Cancer
|
Individualized risk assessment using artificial intelligence and molecular imaging in prostate carcinoma patients
Funding line:
Else Kröner Excellence Fellowships
The advancement of Artificial Intelligence (AI) opens new possibilities in medical imaging analysis. AI algorithms can non-invasively analyze tumors and make prognoses. Collaborating with a group of international medical treatment centers, we are gathering data from prostate cancer patients who have undergone a specific type of molecular imaging (PSMA PET) before radio-oncological treatment. The aim is to develop specialized AI algorithms to improve therapy planning, better characterize tumors, and assist doctors in prognosis assessment. These models will eventually be tested in a clinical trial.
Here you can find further information.